Healthcare / Medical Instruments & SuppliesBSE
$390.00
+0.95 (+0.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $78.9M · quality 32.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.7B
P/E
22.8x
↑EV/EBITDA
15.6x
↑ROE
17.2%
↑Gross Margin
80.3%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.7%
FCF CAGR
+83.7%
FCF margin
20.7%
FCF / Net income
0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $620.8M · net income $181.6M · FCF $128.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $620.8M | $620.8M | $559.1M | $498.5M | $381.1M |
| Net Income | $181.6M | $181.6M | $161.4M | $157.1M | $115.7M |
| EBITDA | $261.5M | $261.5M | $227.1M | $216.3M | $166.8M |
| EPS | 15.13 | 15.13 | 13.45 | 13.09 | 9.64 |
| Gross Margin | 80.3% | 80.3% | 75.8% | 74.7% | 74.3% |
| Operating Margin | 33.0% | 33.0% | 33.6% | 38.4% | 38.6% |
| Net Margin | 29.2% | 29.2% | 28.9% | 31.5% | 30.4% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | — | 0.02 |
| Cash Flow | |||||
| Free Cash Flow | $128.5M | $128.5M | $78.9M | $-28.6M | $20.7M |
| Returns | |||||
| ROE | 17.2% | 17.2% | 18.2% | 21.6% | 20.3% |
| Valuation | |||||
| P/E | 22.83 | 22.83 | 30.62 | 24.45 | 41.49 |
| EV/EBITDA | 15.57 | 15.57 | 19.63 | 15.95 | 26.32 |
| P/B | 4.43 | 4.43 | 5.58 | 5.27 | 8.41 |
| Growth & Yield | |||||
| Revenue Growth | 11.0% | 11.0% | 12.1% | 30.8% | — |
| EPS Growth | 12.5% | 12.5% | 2.8% | 35.8% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
31.8%
EPS terminal req.
$34.61
Spread vs growth
-19.3%
5Y implied EPS CAGR
22.6%
EPS terminal req.
$41.87
Spread vs growth
-10.1%
10Y implied EPS CAGR
16.1%
EPS terminal req.
$67.44
Spread vs growth
-3.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.7%
Start / end P/E
35.3x → 25.8x
EPS bridge
13.45 → 15.13
Residual
-3.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.